Novel drugs are needed for the prevention and treatment of breast cancer. Synthetic triterpenoids are a promising new class of compounds with activity in a variety of preclinical cancer models. We tested activity of the methyl ester derivative of the synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Me), in a relevant model of ER-negative breast cancer, the polyoma-middle T (PyMT), in which the oncoprotein drives carcinogenesis. The developing tumors recapitulate key features of the human disease. Mice were fed CDDO-Me (50 mg/kg diet), starting at 4 weeks of age. CDDO-Me significantly increased the age of mice at onset of first tumor (P < 0.001) by an average of 4.3 weeks and overall survival (P < 0.001) by 5.2 weeks.
Introduction
Breast cancer is the most widely diagnosed cancer and the second leading cause of cancer related deaths in females in the United States (1). The incidence of estrogen receptor positive (ER+) breast cancer has gradually declined largely due to the cessation of hormone replacement therapy; however, the incidence of ER negative (ER-) breast cancer has not changed in over 30 years (2, 3) . To reduce the mortality rates associated with ER-breast cancer, novel drugs and drugs combinations are needed for the prevention and treatment of the disease.
Numerous studies have demonstrated the importance of the tumor microenvironment in carcinogenesis and metastasis (4, 5) , underscoring it as a target for not only cancer therapy, but also for chemoprevention (6, 7) . Tumor-associated macrophages (TAMs) can represent over 50% of the tumor mass in breast cancer patients, and their infiltration correlates with poor prognosis (8, 9, 10) . TAMs activate angiogenesis, providing nutrients, oxygen, and growth factors for the growing tumor (11) (12) (13) and also enhance tumor cell migration, invasion, and intravasation, increasing the metastatic capacity of the malignant tumor (14, 15) . Genetic depletion of macrophages results in a significant delay of tumor progression and inhibition of lung metastasis in the The synthetic oleanane triterpenoids, including 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and CDDO-methyl ester (CDDO-Me), are a promising class of agents for the prevention and treatment of breast cancer. These compounds inhibit proliferation of ER-breast cancer cells in vitro and in vivo (22) (23) (24) . CDDO-Me significantly delayed the development of mammary tumors and arrested growth of established tumors in the MMTV-neu transgenic model of ER-breast cancer (24) .
CDDO-Me inhibits components of commonly deregulated signaling pathways in ER-
breast cancer cells such as the NF-κB and STAT3 pathways (22) (23) (24) . Additionally, CDDO and CDDO-Me suppress factors associated with the tumor microenvironment, including proinflammatory cytokines in primary peritoneal macrophages and in the RAW 264.7 mouse macrophage-like cell line and inhibited angiogenesis in vitro and in vivo (25) (26) (27) (28) . However, the effects of triterpenoids on TAMs have not been elucidated, and our hypothesis was that these drugs could prevent cancer by targeting TAMS. In these studies, we report that the synthetic triterpenoid CDDO-Me delays mammary tumorigenesis in the aggressive PyMT model of ER-breast cancer, and it does have a modest effect on TAM infiltration in the mammary glands and tumors of these mice. It also inhibits the levels of the chemokines CXCL12 and CCL2 in primary PyMT tumor cells and targets the key breast cancer biomarkers cyclin D1, EGFR and STAT3 in these cells.
Materials and Methods
Drugs. CDDO-Me was synthesized as described (29) . For cell culture studies, CDDOMe was dissolved in DMSO, and controls containing equal concentrations of DMSO (<0.1%) were included in all experiments.
Cancer Research. and were genotyped as has been previously described (30, 31) . Four-week-old female PyMT mice were fed powdered 5002 rodent chow (PMI Feeds) or this powdered diet containing CDDO-Me (50 mg/kg diet). Mice were palpated twice a week for detection of new tumors. Tumors were measured weekly with calipers. In accordance to IACUC regulations, death was not used as an end point, but instead mice were sacrificed when symptoms were observed such as tumor mass exceeding 10% of total body mass, obstruction of movement by the tumor or labored breathing. To determine the effects of CDDO-Me on mammopoiesis, both PyMT +/-and PyMT -/-mice (n = 5 per group) were fed either control diet or CDDO-Me in diet from 4 weeks of age until 8-12 weeks of age.
After 4-8 weeks on diet, mammary glands were harvested and whole mounts were stained with hematoxylin. To determine drug levels in tissue, five female PyMT mice were fed CDDO-Me in diet (50 mg/kg diet) for 1 week. Mammary glands were harvested and homogenized in PBS and whole blood was collected in heparinized tubes. Samples were extracted in acetonitrile, separated by reverse phase liquid chromatography, and detected by mass spectrometry. Standard curves were generated by serially diluting known concentrations of CDDO-Me in control blood or tissue homogenates. All samples were within the linear range of the standard curve.
Cancer Research. Macrophage isolation and analysis. Macrophages were isolated from tumors and mammary glands using a dual purification strategy including magnetic purification followed by flow sorting. Single cell suspensions were generated from tumors and mammary glands. Briefly, all tumors and mammary glands were removed and digested in DMEM with 10% fetal bovine serum (FBS) and an enzyme mixture consisting of collagenase (300 U/mL; Sigma), dispase (1.0 U/mL; Worthington), and DNase (2 U/mL; Calbiochem) for 30 min at 37°C. Cells were passed through 40 μm cell strainers (BD Bioscience) and incubated for 15 min with CD11b magnetic beads (Miltenyi Biotec), Effects of treatment with CDDO-Me on survival were also investigated. In accordance to IACUC regulations, mice were sacrificed when symptoms such as tumor mass exceeding 10% of total body mass, obstruction of movement, or labored breathing were observed. In the control group, 50% of mice were sacrificed by week 20 and 100% by week 28. In contrast, 50% of mice fed CDDO-Me diet were sacrificed by week 25, whereas 100% of these mice were sacrificed by week 42 (Fig. 2B) . Thus, CDDO-Me prolonged survival (P < 0.001) in this mouse model of ER-negative breast cancer. 
To determine drug levels of CDDO-Me, PyMT mice were fed CDDO-Me in diet for one week. An average of 1.1 ± 0.2 μM CDDO-Me was detected in the mammary gland but only 20 ± 5 nM was detected in whole blood. Because diets were started at 4 weeks of age and thus before full maturation of the mammary gland, we also examined the effects of CDDO-Me on mammary gland development. Both PyMT +/-and PyMT -/-mice were fed control diet or CDDO-Me (50 mg/kg diet) for 4-8 weeks, and CDDO-Me had no effect on mammopoiesis in mice of either genotype (data not shown). Moreover, no differences in mammary gland maturation were ever observed in sections of mammary glands used for IHC, in mice treated with CDDO-Me for 8-12 weeks (data not shown). (Fig. 3C) .
CDDO-Me inhibits infiltration of TAMs in ER-negative mammary tumors.
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CDDO-Me treatment inhibits secretion of chemokines by PyMT tumor cells.
To investigate a possible mechanism engaged in the modestly reduced infiltration of TAMs in mammary tumors of PyMT mice fed diet containing CDDO-Me, levels of chemokines in isolated primary mammary tumors cells were evaluated. CDDO-Me treatment for 8, 16, or 24 hours resulted in a significant (P < 0.001) dose-dependent decrease in the levels of CCL2 and CXCL12 mRNA detected via RT-PCR as compared to vehicle control (Fig. 4A) . CDDO-Me also inhibited the secretion of CCL2 in a dosedependent manner in primary tumor cells (Fig. 4B) . Thus, CDDO-Me inhibits the production of chemokines capable of attracting TAMs and other inflammatory cells into mammary tumors. proliferation by CDDO-Me, primary PyMT tumor cells were treated with biotinylated CDDO-Me, and lysates were precipitated with immobilized NeutrAvidin followed by western blotting of common components of oncogenic pathways. The biotinylated CDDO-Me directly interacted with EGFR and STAT3 but not with cyclin D1 (Fig. 5C) and inhibited these diverse pathways. Levels of cyclin D1 and phosphorylated EGFR and STAT3 were reduced following CDDO-Me treatment in primary PyMT tumor cells as compared to vehicle (Fig. 5D) 
CDDO-Me inhibits numerous oncogenic pathways in ER-

Discussion
We show in our present study that CDDO-Me is the first known drug to significantly delay tumorigenesis in PyMT mice and that it modestly inhibits the infiltration of TAMs to the tumor site in this extremely aggressive model of ER-breast cancer. These findings parallel results from previous studies where genetic depletion of TAMs in PyMT mice delay the progression of primary tumors but has no effect on the formation or growth of these tumors (16) and indicate that a pharmacologic agent can achieve similar effects to that of genetic approaches. Macrophage infiltration to the tumor site in response to inflammatory cytokines activates them to produce chemokines 
other chemopreventive agents such as LG100268 (51). As previously mentioned, CDDO-Me did not induce apoptosis via annexin staining in primary PyMT tumor cells, even though it does induce apoptosis by a variety of mechanisms in cancer cells in vitro (25) . We did not explore a wide variety of doses, especially higher doses, for effects of apoptosis in our current study or compare the effects of CDDO-Me on normal, premalignant, and malignant cells. We are beginning these studies and investigating whether CDDO-Me has an effect on established tumors in the PyMT model as CDDOMe has been shown to induce apoptosis in a variety of human ER-negative breast cancer cells (25) and arrest tumor growth in the MMTV-neu transgenic model of ERbreast cancer (24) . The effects of CDDO-Me on multiple pathways and cells undoubtedly contribute to its efficacy in the PyMT model for the prevention of experimental breast cancer, and defining all of the mechanisms of action for this drug remains an area of active investigation.
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